Trispan Dosage/Direction for Use

Posology: Intraarticular Therapy: Intra-articular injections are to be regarded in the same way as open joint surgery and must only be performed under strictly aseptic conditions. In general, a single intra­articular injection of TRISPAN is sufficient for successful symptomatic relief. If another injection is deemed necessary, it should not be given for at least another 3 - 4 weeks, the number of injections per joint should be restricted to 3 - 4. Especially after repeated injection, medical check-ups of the treated joint are indicated.
The dosage depends on the size of the joint and the severity of the findings. The following dosage statements may serve as a guideline: Large joints 10 - 20 mg, medium­-sized joints 5 - 10 mg, small joints 2 - 5 mg triamcinolone hexacetonide.
Paediatric population: In accordance with the German interdisciplinary and evidence-based guideline by the German Society for Paediatric and Adolescent Rheumatology for the treatment of juvenile idiopathic arthritis, administration of 0.5-1 mg/kg BW triamcinolone hexacetonide is recommended for the treatment of large joints. For smaller joints, the dosage should be reduced accordingly.
Sub- and intralesional therapy: The dosage and method of injection are determined by the nature, location and extent of lesions and the clinical picture.
The dose per single injection should not exceed 0.1 mg triamcinolone hexacetonide per cm² of the skin surface area.
When administered via this route, Trispan should generally be diluted at a ratio of at least 1:1.
Good therapeutic responses are also achieved at a dilution of 1:5.
Paediatric population: No data are available.
Infiltration therapy: The doses depends on the extent and location of the injection site, as well as the severity of symptoms, and can be between 2 and 20 mg triamcinolone hexacetonide.
Trispan is infiltrated into the area of most intense pain or the tendon attachments.
Cautions: do not inject into the tendon. Injections at short intervals should be avoided; strict aseptic conditions must be observed.
Paediatric population: No data are available.
Method of administration: Precautions to be taken before handling or administering the medicinal product: TRISPAN can be injected via the intra-articular, sublesional and intralesional routes or used for infiltration therapy. TRISPAN must not be injected intravenously. Injections into adipose tissue should also be avoided, as circumscribed cellulite formation may possibly occur as a result of subcutaneous adipose tissue atrophy.
If pain should occur during the injection, it should be discontinued immediately.
For instructions on reconstitution/dilution of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions for Usage.